Association between exposure to adalimumab (ADA), etanercept (ETA) or infliximab (INF) and lymphoma
| ADAN=4288 | ETA N=4144 | INF N=3499 | |
|---|---|---|---|
| First TNFi received (censored when second biological drug started)* | |||
| Total follow-up time (pyrs) | 22 361 | 26 838 | 17 688 |
| Number of lymphomas | 20 | 20 | 18 |
| Incidence rate per 100 000 pyrs (95% CI) | 89 (55 to 138) | 75 (45 to 115) | 102 (60 to 161) |
| PD-adjusted HR (95% CI) (csDMARD referent) | 1.00 (0.49 to 2.03) | 1.02 (0.45 to 2.33) | 0.91 (0.39 to 2.13) |
| Most recently received TNFi | |||
| Follow-up time (pyrs) | 33 354 | 40 618 | 21 149 |
| Number of lymphomas | 34 | 29 | 21 |
| Incidence rate per 100 000 pyrs (95% CI) | 102 (71 to 143) | 71 (48 to 103) | 99 (62 to 152) |
| PD-adjusted HR (95% CI) (csDMARD referent) | 0.99 (0.52 to 1.88) | 0.78 (0.37 to 1.66) | 0.82 (0.37 to 1.82) |
| On drug (plus 90 days)*† | |||
| Follow-up time (pyrs) | 18 818 | 24 984 | 12 328 |
| Number of lymphomas | 23 | 10 | 10 |
| Incidence rate per 100 000 pyrs (95% CI) | 122 (77 to 183) | 40 (19 to 74) | 81 (39 to 149) |
| PD-adjusted HR (95% CI) (csDMARD referent) | 0.77 (0.37 to 1.61) | 0.41 (0.14 to 1.19) | 0.75 (0.27 to 2.09) |
*Time after last received consultant follow-up form excluded from these analyses.
†Includes both first and subsequent exposures to the drug.
pyrs, patient-years; TNFi, tumour necrosis factor inhibitors.